Reprint News release (SEOUL, South Korea, May 25, 2022) Hyundai Bioscience will go straight to the US with its broad-spectrum antiviral drug candidate to treat monkeypox. Hyundai Bioscience has decided to submit a request for a fast track processing to the U.S. Food and Drug Administration (FDA) for CP-COV03, an oral antiviral medicine…
Reprint News release (May 25, 2022 03:00 AM Eastern Daylight Time) DAVOS, Switzerland--Pfizer Inc. (NYSE: PFE) today launched ‘An Accord for a Healthier World.’ This groundbreaking initiative aims to provide all of Pfizer’s patented, high-quality medicines and vaccines available in the U.S. or the European Union on a not-for-profit basis to 1.2…
Reprint News release (28 November 2017) WHO urges governments to take action An estimated 1 in 10 medical products circulating in low- and middle-income countries is either substandard or falsified, according to new research from WHO. This means that people are taking medicines that fail to treat or prevent disease. Not…
Vientiane,Laos PDR, May 21, 2022 /LienTeh/ Yesterday,Members of several leading pharmaceutical companies in Laos discussed the spread of monkeypox and reached a preliminary plan. Companies involved in the formulation of the plan include:RxLibra、SaiLin-Bio、BioSpring、DAXIONG Pharma...etc. The above companies initially selected Tecovirimat as the treatment drug for monkeypox, and started to study the production…
ປະກາດການໂຄສະນາການຈ້າງງານຟຣີ -ການລະບາດຂອງພະຍາດໂຄວິດ-19 ໃນທົ່ວໂລກໄດ້ຂັດຂວາງການພັດທະນາເສດຖະກິດ ແລະ ການຈ້າງງານຫຼຸດລົງ. ໂຄງການ ALBA Connect ມີຈຸດປະສົງເພື່ອຊ່ວຍໃຫ້ພະນັກງານໃນລາວຊອກຫາໂອກາດວຽກເຮັດງານທຳໃນອຸດສາຫະກຳການຢາ. ພວກເຮົາຈະໂຄສະນາໂຄງການອອນໄລນ໌ແລະໃນຕົວເມືອງ, ໂດຍສະເພາະພວກເຮົາຈະລົງໂຄສະນາແລະໂປສເຕີໃນມະຫາວິທະຍາໄລ, ເມືອງທຸລະກິດ. ເງື່ອນໄຂການເຂົ້າຮ່ວມໂຄງການ ສະຖາບັນທີ່ເຂົ້າຮ່ວມຕ້ອງຕອບສະຫນອງເງື່ອນໄຂພື້ນຖານຕໍ່ໄປນີ້ໃນເວລາດຽວກັນ. ຮັບສະເພາະສິ່ງພິມຈາກສະຖາບັນ ປະຈຸບັນການປະກາດຮັບສະໝັກວຽກຈາກອົງການ ຫຼື ອົງການຈັດຕັ້ງໃນຂະແໜງອຸດສາຫະກຳການແພດ ແລະ ຮ້ານຂາຍຢາ. ປະກາດຮັບສະໝັກວຽກແມ່ນໄດ້ຜ່ານ: [HR-Nith] ຢູ່ໃນ [ຊ່ອງທາງວຽກ] ຂອງ lienTeh. ປະເພດອົງການຈັດຕັ້ງ ສະຖາບັນການແພດ: ໂຮງຮຽນການແພດ, ໂຮງຫມໍ, ຄລີນິກ, ໂຮງງານຜະລິດຢາ, ຮ້ານຂາຍຢາ, ບໍລິສັດການຄ້າ, ແລະອື່ນໆ. ທີມກູ້ໄພ: ທີມງານກູ້ໄພການແພດແລະທີມກູ້ໄພມືອາຊີບອື່ນໆ. ອົງການຈັດຕັ້ງອື່ນໆ: ເຊັ່ນ: ສະມາຄົມອຸດສາຫະກໍາຢາ, ແລະອື່ນໆ. ຂໍ້ມູນວຽກ 1. ໂລໂກ້ຂອງບໍລິສັດຮັບສະໝັກພະນັກງານ. 2. ເອກະສານລະອຽດໃນການສະໝັກຕໍາແໜ່ງງານ. 3. ຂໍ້ມູນຕິດຕໍ່ HR ຂອງບໍລິສັດຮັບສະໝັກ.…
TOKYO, November 5, 2021 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it obtained approval from the Ministry of Health, Labour and Welfare (MHLW) for the anti-SARS-CoV-2 monoclonal antibody RONAPREVE® [generic name: casirivimab (genetical recombination) /imdevimab (genetical recombination)] for the additional indication of the prevention of symptomatic SARS-CoV-2 infection (COVID-19). The Special…
FREIENBACH, Switzerland–04.11.2021 EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced that Swissmedic has approved Bronchitol® (inhaled mannitol) for the treatment of cystic fibrosis (CF) in adults and in children aged 6 years and above as add‐on to other medicines. The clinical…
KENILWORTH, N.J. & MIAMI--November 4, 2021 Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization in the United Kingdom (U.K.) for molnupiravir (MK-4482, EIDD-2801), the first oral antiviral…
28th October 2021 The European Medicines Agency (EMA) has approved Bioprojet’s Ozawade (pitolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnoea (OSA) in adults. Ozawade was evaluated in two Phase III clinical studies in the treatment of EDS in patients suffering from OSA – HAROSA…
MISSISSAUGA, ON, Oct. 29, 2021 Libtayo® (cemiplimab) is now approved in Canada for the treatment of adults with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI).The approval of Libtayo follows the European Commission (EC) approval announced in June 2021 and the US in February 2021. With today's announcement, Libtayo is now offered as…